Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11680MR)

This product GTTS-WQ11680MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11680MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5688MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ3471MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ10862MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ8623MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ4862MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ7953MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4751MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ3624MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW